Autoantibodies to native myeloperoxidase in patients with pulmonary hemorrhage and acute renal failure

1991 ◽  
Vol 11 (6) ◽  
pp. 389-397 ◽  
Author(s):  
Douglas E. Roberts ◽  
Carol Peebles ◽  
John G. Curd ◽  
Eng M. Tan ◽  
Robert L. Rubin
2010 ◽  
Vol 49 (14) ◽  
pp. 1401-1403 ◽  
Author(s):  
Yoshikata Morita ◽  
Mako Yasuda ◽  
Mitsushige Nakao ◽  
Yoshinori Tsujimura ◽  
Motohide Isono

2001 ◽  
Vol 34 (8) ◽  
pp. 1205-1210
Author(s):  
Yoshiaki Nishioka ◽  
Yasuhide Kanamoto ◽  
Hiroshige Kawano ◽  
Masanobu Miyazaki ◽  
Takashi Harada ◽  
...  

2021 ◽  
Vol 8 ◽  
Author(s):  
Chien-Chou Chen ◽  
Hsin-Yang Chen ◽  
Chun-Chi Lu ◽  
Shih-Hua Lin

The rare and severe adverse effects associated with coronavirus disease of 2019 (COVID-19) vaccination have been under-appreciated, resulting in many instances of inappropriate management. We describe the case of an elderly woman who developed anti-neutrophil cytoplasmic antibody-associated vasculitis with pulmonary renal syndrome approximately 3 weeks after the first dose of COVID-19 mRNA vaccination (Moderna). Her nasopharyngeal polymerase chain reaction test for the COVID-19 RNA virus was negative. Gross hematuria, heavy proteinuria, acute renal failure (serum creatinine up to 6.5 mg/dL), and hemoptysis coupled with a marked increase in serum anti-myeloperoxidase-O antibody were observed. Renal biopsy showed severe vasculitis with pauci-immune crescent glomerulonephritis. The pulmonary hemorrhage was resolved and renal function improved following combined plasma exchange and the administration of systemic steroids and anti-CD20 therapy. The early examination of urinalysis and renal function may be crucial for identifying glomerulonephritis and acute renal failure in susceptible patients after COVID-19 vaccination.


2020 ◽  
Vol 8 (T1) ◽  
pp. 542-547
Author(s):  
Biljana Gerasimovska-Kitanovska ◽  
Gjulshen Selim ◽  
Zvezdana Petronijevik ◽  
Blagica Pecanova ◽  
Gjorgi Stojchev ◽  
...  

BACKGROUND: Antineutrophil cytoplasmatic antibody (ANCA)-associated vasculitis (AAV) has a predilection for the kidney and more than three quarters of patients have renal involvement with rapidly progressive glomerulonephritis. Small-vessel systemic vasculitis may present as pulmonary-renal syndrome and is characterized by necrotizing glomerulonephritis and pulmonary hemorrhage. Diagnosis and therapy for AAV in coronavirus disease (COVID) COVID-19 pandemic require multi-disciplinary collaboration due to the affection of multiple systems and risks associated with immunosuppressive medications. CASE REPORT: A 69-year-old non-smoker, non-diabetic female presented in the outpatient unit at the department of pulmonology with dry cough, malaise, and sub-febrile temperature, lasting for 1 month. The patient had a high suspicion of severe pulmonary-renal syndrome, ANCA-AAV, and acute renal failure requiring hemodialysis. She was treated with corticosteroids, cyclophosphamide, and plasma exchange. The treatment led to temporary improvement. Infections with COVID-19, Enterococcus in the urine, and Acinetobacter in the tracheal aspirate further complicated the clinical picture and despite antibiotic treatment, use of tocilizumab and convalescent plasma, the outcome was lethal. CONCLUSION: It is important to establish the diagnosis and distinguish accurately between vasculitis and infection to provide adequate and timely therapy.


Sign in / Sign up

Export Citation Format

Share Document